💊 Akums Q4 & FY25 Results: India’s CDMO King Posts ₹234 Cr Profit — Europe Entry Unlocked, EBITDA Steady, Growth Mode ON

💊 Akums Q4 & FY25 Results: India’s CDMO King Posts ₹234 Cr Profit — Europe Entry Unlocked, EBITDA Steady, Growth Mode ONCMP: ₹587.50 | Up 0.96% | P/E: 25.1x | Adj. EBITDA Margin: 12.3% | Europe Contract: €200M

📌 At a Glance

Akums Drugs and Pharmaceuticals Ltd. clocked ₹1,073 Cr revenue in Q4 FY25 (up 12.4% YoY) and wrapped FY25 with ₹4,170 Cr total income. Adjusted PAT for the year stood at ₹234 Cr, with a solid 12.3% EBITDA margin despite industry-wide price erosion. Oh, and they’ve bagged a €200 million contract for Europe. Not bad for a debut fiscal year post-listing.

🧪 About Akums

• HQ: New Delhi, India
• Listed On: NSE (AKUMS), BSE (544222)
• Business: Largest Indian CDMO (Contract Development & Manufacturing Organization)
• Segments: CDMO, Branded Formulations (Domestic & International), Trade Generics, APIs
• Capacity: 49.6 billion units/year
• Approvals: 973 DCGI approvals, 4,000+ commercialised formulations

If Indian pharma was a film, Akums is the DOP — never in frame, but making everyone look good.

🧑⚕️ Key Management

“Our injectable facility is live, our R&D